INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, INTEGRA LIFESCIENCES HOLDINGS CORP's filing signal turned negative.

Integra LifeSciences Holdings Corporation is a global medical technology company focused on restoring lives through innovative and differentiated technologies. The company operates through two primary segments: Codman Specialty Surgical (CSS), which accounts for approximately 70% of revenue and includes neurosurgery, neurocritical care, and ENT products, and Tissue Technologies (TT), representing about 30% of revenue, focusing on wound reconstruction, care, and private label offerings. Integra is a world leader in neurosurgery and a top three U.S. provider of instruments for precision surgical procedures. Its Tissue Technologies segment is a leader in regenerative technology, offering solutions for wound care and tissue repair derived from various biomaterials. The company sells its products globally through a combination of direct sales representatives and independent distributors.

Revenue is primarily driven by sales within the Codman Specialty Surgical segment, particularly in neurosurgery, and the Tissue Technologies segment, which includes wound reconstruction and care products. Growth is supported by new product introductions, geographic expansion, and strategic acquisitions.